Testing a new cancer drug plus capecitabine for metastatic colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 or older and can give written informed consent
- You have confirmed colorectal cancer that has spread to sites that cannot be removed by surgery
- Your cancer has not responded to at least two rounds of standard chemotherapy (including fluorouracil-type drugs, oxaliplatin, and irinotecan)
- You can have imaging tests showing at least one measurable or trackable spot of cancer
- Your overall health is good enough for study treatment (ECOG 0–1)
- You can safely use birth control during the study and for a set time after the last dose (if you could become pregnant or have a partner who could)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a combination of two oral drugs, capecitabine and lenvatinib, in people with advanced colorectal cancer that has stopped responding to three common chemotherapy drugs. It aims to see if this new combination can help shrink tumors or slow cancer growth.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.